DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 16, 2024 at 01:27 pm IST
Share
DongKook Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 3,001.67 million compared to KRW 3,547 million a year ago. Net income was KRW 19,682.19 million compared to KRW 16,033.29 million a year ago.
Basic earnings per share from continuing operations was KRW 448 compared to KRW 365 a year ago. Diluted earnings per share from continuing operations was KRW 440 compared to KRW 358 a year ago. Basic earnings per share was KRW 448 compared to KRW 365 a year ago.
Diluted earnings per share was KRW 440 compared to KRW 358 a year ago.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
DONGKOOK PHARMACEUTICAL CO., LTD. 
